Tags

Type your tag names separated by a space and hit enter

The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
Eur Urol. 2007 Jan; 51(1):199-203; discussion 204-6.EU

Abstract

OBJECTIVES

To evaluate the relationship between metabolic syndrome and annual prostatic growth rates in benign prostatic hyperplasia (BPH) patients.

METHODS

The 78 BPH patients with lower urinary tract symptoms included in this prospective study were divided into two groups according to whether they had a diagnosis of metabolic syndrome. This diagnosis was made according to the most recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. Blood pressure, body weight, body height, and waist and hip circumferences were measured. The body mass index (BMI) and waist-to-hip ratio (WHR) were calculated. Biochemical analyses including serum glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), insulin, and prostate-specific antigen (PSA) were performed. Total prostate (TP) volume and transitional zone (TZ) volume were measured by transrectal ultrasound. Annual TP and TZ growth rates were calculated.

RESULTS

BPH patients with metabolic syndrome (first group) had significantly higher median body weight, BMI, serum glucose, serum triglyceride, and PSA levels but lower serum HDL-C level, compared with BPH patients without metabolic syndrome (second group, p<0.05). Median annual TP growth rate (1.0 ml/yr) and median annual TZ growth rate (1.25 ml/yr) were significantly higher in the first group versus the second group (0.64 ml/yr and 0.93 ml/yr, respectively, p<0.05).

CONCLUSIONS

The present study demonstrates a further increase in prostate growth in BPH patients with metabolic syndrome. Future studies are needed to confirm our results and to explain underlying mechanisms.

Authors+Show Affiliations

Department of Urology, Numune Education and Research Hospital, Ankara, Turkey. cuneytozden@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

16806666

Citation

Ozden, Cuneyt, et al. "The Correlation Between Metabolic Syndrome and Prostatic Growth in Patients With Benign Prostatic Hyperplasia." European Urology, vol. 51, no. 1, 2007, pp. 199-203; discussion 204-6.
Ozden C, Ozdal OL, Urgancioglu G, et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007;51(1):199-203; discussion 204-6.
Ozden, C., Ozdal, O. L., Urgancioglu, G., Koyuncu, H., Gokkaya, S., & Memis, A. (2007). The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. European Urology, 51(1), 199-203; discussion 204-6.
Ozden C, et al. The Correlation Between Metabolic Syndrome and Prostatic Growth in Patients With Benign Prostatic Hyperplasia. Eur Urol. 2007;51(1):199-203; discussion 204-6. PubMed PMID: 16806666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. AU - Ozden,Cuneyt, AU - Ozdal,Ozdem Levent, AU - Urgancioglu,Guvenc, AU - Koyuncu,Hakan, AU - Gokkaya,Serkan, AU - Memis,Ali, Y1 - 2006/06/14/ PY - 2006/03/17/received PY - 2006/05/29/accepted PY - 2006/6/30/pubmed PY - 2007/3/21/medline PY - 2006/6/30/entrez SP - 199-203; discussion 204-6 JF - European urology JO - Eur Urol VL - 51 IS - 1 N2 - OBJECTIVES: To evaluate the relationship between metabolic syndrome and annual prostatic growth rates in benign prostatic hyperplasia (BPH) patients. METHODS: The 78 BPH patients with lower urinary tract symptoms included in this prospective study were divided into two groups according to whether they had a diagnosis of metabolic syndrome. This diagnosis was made according to the most recent consensus report of the National Cholesterol Education Program's Third Adult Treatment Panel. Blood pressure, body weight, body height, and waist and hip circumferences were measured. The body mass index (BMI) and waist-to-hip ratio (WHR) were calculated. Biochemical analyses including serum glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), insulin, and prostate-specific antigen (PSA) were performed. Total prostate (TP) volume and transitional zone (TZ) volume were measured by transrectal ultrasound. Annual TP and TZ growth rates were calculated. RESULTS: BPH patients with metabolic syndrome (first group) had significantly higher median body weight, BMI, serum glucose, serum triglyceride, and PSA levels but lower serum HDL-C level, compared with BPH patients without metabolic syndrome (second group, p<0.05). Median annual TP growth rate (1.0 ml/yr) and median annual TZ growth rate (1.25 ml/yr) were significantly higher in the first group versus the second group (0.64 ml/yr and 0.93 ml/yr, respectively, p<0.05). CONCLUSIONS: The present study demonstrates a further increase in prostate growth in BPH patients with metabolic syndrome. Future studies are needed to confirm our results and to explain underlying mechanisms. SN - 0302-2838 UR - https://www.unboundmedicine.com/medline/citation/16806666/The_correlation_between_metabolic_syndrome_and_prostatic_growth_in_patients_with_benign_prostatic_hyperplasia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0302-2838(06)00657-9 DB - PRIME DP - Unbound Medicine ER -